Date: 2015-01-26
Type of information: Capital increase
Company: Acticor Biotech (France)
Investors: investors of the French equity crowdfunding platform Anaxago (France) and business angels
Amount: € 0.59 million
Funding type: capital increase
Planned used: Founded in late 2013, the Inserm spin-off Acticor Biotech will use the funds to launch the development of its core product ACT-017. This humanized antibody is directed against a new target of major interest for the treatment of cerebral stroke, the platelet glycoprotein VI (GPVI). This drug candidate is based on scientific research from two Inserm units and was lead by Drs Martine Jandrot-Perrus (U1148) and Christian Gachet (U949), and by Pr. Philippe Billiald from the Institut Paris-Sud d’Innovation Thérapeutique. Acticor Biotech will develop this anti-GPVI antibody as a platelet-aggregation inhibitor for acute thrombotic pathologies.The company is presently closing the drug discovery phase of the development by optimizing the compound for industrial production and the preclinical phase will start as soon as the seed funding is secured.
Others: * On January 26, 2015, Acticor Biotech, a biotech company dedicated to the development of an emergency treatment of ischemic stroke, announced the successful closing of its first capital increase for a total of €590,000. This amount, raised from investors of the crowdfunding platform Anaxago and Business Angels, enables the young Inserm (French National Institute of Health and Medical Research) spin-off to launch the development of its product. With two thirds of the capital increase raised with the equity crowdfunding platform Anaxago, Acticor Biotech becomes one of the first companies to successfully raise equity crowd-funds for therapeutic biotechnologies. The level of investors interest in this project demonstrates the strong will of participants to support the development of innovative solutions addressing major public health concerns. This capital increase takes place as Acticor just signed an agreement with Genopole that will allow the company to join the biocluster and benefit from services to support its structural development and growth.
Therapeutic area: Cardiovascular diseases - Cerebrovascular diseases
